- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002373
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
A Phase I/II Trial to Evaluate the Tolerability, Anti-CMV Activity and Pharmacokinetics of 1263W94 Following Multiple Oral Administration of Escalating Doses in HIV-Infected Patients With Asymptomatic CMV Shedding
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Univ of California/ San Francisco / Dept of Medicine
-
San Francisco, California, United States, 94115
- Dr Jacob Lalezari
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Concurrent Medication:
Allowed:
Stable, chronically administered concomitant therapy for HIV infection and opportunistic diseases if patient has been on the regimen for at least one month prior to study entry.
Patients must have:
Required of Main group:
- Minimum CMV titer of 5000 PFU/ml in semen by quantitative CMV culture on one occasion within 30 days of entry.
- Demonstrating positive result of qualitative CMV culture in urine on one occasion within 30 days of entry.
Required of Satellite group:
- Must have CD4+ < 150 c/mm3 (or 10% of total lymphocytes) at screen.
Required of both groups:
- HIV infection.
- Life expectancy > 6 months.
- Able to comply with protocol requirements/instructions and likely to complete all study visits and evaluations as planned.
Prior Medication:
Allowed:
Stable, chronically administered concomitant therapy for HIV infection and opportunistic diseases for at least one month prior.
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
- Active CMV disease (retinitis, colitis, encephalitis, pneumonitis, etc.).
- Visual symptoms or signs suggestive of CMV disease (e.g., floaters, visual field defects, decreased visual acuity); Unless CMV disease is excluded via ophthalmoscopy examination.
- Active hepatitis, obstructive hepatobiliary diseases or cirrhosis.
- Gastrointestinal disorders which, in the judgement of the investigator, might interfere with oral dosing and drug absorption or may be indicative of CMV disease e.g., chronic nausea or vomiting, active bowel disease or persistent diarrhea.
- Diagnosis of chronic diseases such as diabetes or hypoglycemia, epilepsy, ongoing Grade II peripheral neuropathy, congestive heart failure, cardiomyopathy, other organ dysfunctions, etc., which in the opinion of the investigator, would compromise the safety or compliance of the patient.
- Participation in other investigational trials.
- Patients who are so debilitated as a result of their HIV disease or associated illness or therapies such that, in the investigator's opinion, the condition may interfere with the study assessments or the patient's ability to complete the entire study per protocol requirements.
Concurrent Medication:
Excluded:
Systemic therapy for visceral malignancy.
Concurrent Treatment:
Excluded:
Treatment with radiation therapy for visceral malignancy.
Patients with any of the following prior symptoms or conditions are excluded:
- History of CMV disease (such as retinitis, colitis, encephalitis, pneumonitis, etc.)
- Known history of lactose intolerance.
Prior Medication:
Excluded:
- Systemic therapy for visceral malignancy within 2 months prior to entry.
- Prior treatment with ganciclovir, foscarnet, cidofovir, or other investigational anti-CMV drugs (e.g., intravenous acyclovir, lobucavir, valacyclovir) within 2 months prior to entry.
- Treated with interferons, immunomodulators or CMV hyperimmune globulin within 1 month prior to entry.
- Any investigational therapies within 1 month prior of study entry.
Prior Treatment:
Excluded:
- Treatment with radiation therapy for visceral malignancy within 2 months prior to entry.
- Treatment with any investigational treatments within 1 month of study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Interventional Model: PARALLEL
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 263A
- CMAA1003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Maribavir
-
ShireCompleted
-
ShireCompletedCytomegalovirus InfectionsUnited States, Canada, United Kingdom, Germany, France, Belgium, Italy, Spain, Sweden
-
TakedaCompletedHealthy VolunteersUnited States
-
TakedaTakeda Development Center Americas, Inc.Completed
-
TakedaTakeda Development Center Americas, Inc.RecruitingCytomegalovirus (CMV)France, United Kingdom, Israel, Germany, Spain, Belgium, China, Brazil, United States, Japan
-
ShireCompletedCytomegalovirus (CMV)United States
-
TakedaCompletedCytomegalovirus (CMV)Japan
-
ShireTakeda Development Center Americas, Inc.CompletedCytomegalovirus (CMV)United States, China, Spain, Belgium, Australia, Germany, Italy, Canada, France, Croatia, Singapore, United Kingdom, New Zealand, Korea, Republic of, Russian Federation, Poland, Austria, Greece, Switzerland, Czechia, Hungary, Israel, Turk...
-
ShireCompleted
-
ShireCompletedCytomegalovirus InfectionsUnited States